Cancer drug combo trial halted early after only 13 patients

NCT ID NCT05588609

Terminated Disease control Sponsor: Partner Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called zenocutuzumab combined with other medicines in people with two types of cancer: non-small cell lung cancer with a specific gene change (NRG1 fusion) and advanced prostate cancer that no longer responds to hormone therapy. The goal was to see if the combinations could shrink tumors or lower PSA levels. The trial was stopped early after enrolling only 13 participants, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER NSCLC HARBORING NRG1 FUSION

Contacts and locations

Locations

Florida Cancer Specialists

Lake Mary, Florida, 32746, United States
Memorial Sloan Kettering Cancer Center

New York, New York, 10065, United States
Northwest Medical Specialties

Tacoma, Washington, 98405, United States
The Center for Cancer and Blood Disorders

Bethesda, Maryland, 20817, United States
The Oncology Institute of Hope & Innovation

Whittier, California, 90603, United States
TriHealth Cancer Institute

Cincinnati, Ohio, 45220, United States
University Hospitals - Seidman Cancer Center

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.